Researcher Yoshida from Safety BU to Present a Poster at the 54th Annual Meeting of Japanese Environmental Mutagen and Genome Society (JEMS)

2025.11.11

Researcher Yoshida from the Safety Business Unit, will deliver a poster presentation at the 54th Annual Meeting of the Japanese Environmental Mutagen and Genome Society (JEMS), to be held from November 22 to 23 in Shizuoka prefecture, Japan.
If you plan to attend the conference, we encourage you to join the session and hear the presentation.

Conference Name:the 54th Annual Meeting of the Japanese Environmental Mutagen and Genome Society (JEMS)

Date & Time: November 23, 13:45-14:45 (JST)

Location: University of Shizuoka, Kusanagi Campus, Shizuoka prefecture, Japan

Title: Evaluation of γH2AX Assay for Screening Chromosomal Aberrations

Poster number: P-50

Presentation Summary
Detection of chromosomal structural abnormalities at the late stage of drug development can cause significant delays or lead to even project termination, making early screening during the discovery stage essential.
Recently, nucleic acid-binding small molecules (NBSMs) have raised concerns about chromosomal aberrations caused by DNA damage, highlighting the need for faster and more sensitive evaluation methods that can be applied at the discovery stage.
We assessed the applicability of a γH2AX-based assay capable of sensitively detecting DNA strand breaks for screening chromosomal structural abnormalities.
Compared to the widely used exploratory in vitro micronucleus test (MicroFlow method), the γH2AX assay requires less than one-tenth of the sample amount and can be completed in only five days. The assay achieved an accuracy of 85% for known chromosomal aberration inducers and 87.5% for NBSMs. Furthermore, non-genotoxic apoptosis inducers that were sometimes misclassified as positive in the micronucleus test were correctly identified as negative in the γH2AX assay.
We believe that the γH2AX assay can be a useful tool for screening chromosomal structural abnormalities.

Axcelead DDP’s Soulution
At Axcelead, we offer in vitro exploratory safety screening services to support the lead optimization process. In the field of genotoxicity assessment, we provide a wide range of services beyond the γH2AX assay. Depending on the characteristics and challenges of each project and compound, we propose the most suitable genotoxicity evaluation strategy tailored to our clients’ specific needs. Please feel free to contact us if you require any assistance or consultation.